Replies to post #8842 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

We plan to file Lunsumio subcut in the second half of 2024 with global regulators. (I haven't really looked into this but I am assuming Halo is not involved and I wonder if any other company is.)

It appears you are correct that it is not associated with HALO. The last Halozyme slide set shows only one other Roche indication in the pipeline and it is in ph1.